Table 2.
Major clinical end points (intention-to-treat population)
| Endpoint | Colchicine | Placebo | Hazard ratio (95%CI) | P value |
|---|---|---|---|---|
| Total MACE | 8 (6.7) | 28 (21.7) | 3.52 (1.60–7.74) | 0.001 |
| ACS | 4 (3.3) | 25 (19.4) | 1.82 (1.49 – 2.23) | < 0.001 |
| STEMI | 0 | 3 (2.3) | 1.95 (1.72 – 2.20) | 0.093 |
| NSTEMI | 2 (1.7) | 8 (6.2) | 1.58 (1.13 – 2.20) | 0.069 |
| UA | 2 (1.7) | 14 (10.9) | 1.77 (1.41 – 2.22) | 0.003 |
| DHF | 0 | 1 (0.8) | 1.93 (1.71 – 2.18) | 0.334 |
| Death | ||||
| any cause | 4 (3.3) | 2 (1.6) | 0.63 (0.20 – 1.99) | 0.359 |
| cardiovascular | 4 (3.3) | 2 (1.6) | 0.63 (0.20 – 1.99) | 0.359 |
Cox regression model clustered over multiple events with an individual and adjusted for group
assignment.ACS, acute coronary syndrome; NSTEMI, non-ST segment elevation acute coronary syndrome; UA, unstable angina; DHF, decompensated heart failure